NEFL and Parkinson disease: We utilized the NULISA CNS Disease Panel, which includes validated AD biomarkers (p-tau217, p-tau181, TREM2) alongside key proteins associated with PD (SNCA, pSNCA-129), FTD (TDP-43), and general neurodegeneration (NEFL, GFAP, NRGN, SMOC1).